Cargando…

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor

Detalles Bibliográficos
Autores principales:	Opalinska, Marta, Lezaic, Luka, Decristoforo, Clemens, Kolenc, Petra, Mikolajczak, Renata, Studen, Andrej, Simoncic, Urban, Virgolini, Irene, Trofimiuk-Muldner, Malgorzata, Garnuszek, Piotr, Rangger, Christine, Fani, Melpomeni, Glowa, Boguslaw, Skorkiewicz, Konrad, Hubalewska-Dydejczyk, Alicja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Image of the Month
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611881/ https://www.ncbi.nlm.nih.gov/pubmed/37452871 http://dx.doi.org/10.1007/s00259-023-06335-9

Ejemplares similares

Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors
por: Opalińska, Marta, et al.
Publicado: (2022)

[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
por: Lezaic, Luka, et al.
Publicado: (2022)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study
por: Erba, Paola A., et al.
Publicado: (2018)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
por: Novruzov, Fuad, et al.
Publicado: (2021)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

Development of the (99m)Tc-Labelled SST(2) Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study
por: Novak, Doroteja, et al.
Publicado: (2023)

CYP3A4 inhibitors do not influence [(68)Ga]Ga-DOTA-TATE uptake in liver tissue
por: Chahid, Youssef, et al.
Publicado: (2023)

The development of guidelines for management of thyroid diseases in pregnancy – current status
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2015)

Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin
por: Papadakis, Georgios Z., et al.
Publicado: (2017)

A false positive 68Ga-DOTA-TATE involvement in an adrenal mass: Kaposi Sarcoma
por: Ozbas, Burak, et al.
Publicado: (2023)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

SAT-575 Radiolabeled Somatostatin Receptor Analog (86)Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 in Thyroid Cancer Mice Models
por: Thakur, Shilpa, et al.
Publicado: (2019)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Postoperative [(68)Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
por: Teske, Nico, et al.
Publicado: (2023)

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
por: Pawlak, Dariusz, et al.
Publicado: (2016)

The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019)

Personal dose equivalent H(p)(0.07) during (68)Ga-DOTA-TATE production procedures
por: Wrzesień, M., et al.
Publicado: (2023)

Al[(18)F]F-NOTA-Octreotide Is Comparable to [(68)Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
por: Haeger, Arlette, et al.
Publicado: (2023)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

FRI491 The Impact Of Insulin Resistance On Thyroid Function In Pregnancy
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2023)

FRI489 The Interplay Between Thyroid Nodular Disease And Insulin Resistance Indices In Pregnant Women
por: Jerzy Nowak, Andrzej, et al.
Publicado: (2023)

[(68)Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis
por: Haubner, Roland, et al.
Publicado: (2016)

SAT-618 Ectopic Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma of the Nasopharynx Diagnosed by (68)Ga-DOTA-TATE PET/CT
por: Kim, Stephanie, et al.
Publicado: (2019)

The Impact of Total Variation Regularized Expectation Maximization Reconstruction on (68)Ga-DOTA-TATE PET/CT Images in Patients With Neuroendocrine Tumor
por: Liu, Lin, et al.
Publicado: (2022)

MON-013 Nutritional Approach To Autoimmune Thyroiditis (AIT) - The Patients’ And Medical Professionals’ View.
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2019)

PSAT384 Familial Non-Medullary Thyroid Cancer — Does The Number Of Alanine Residues In The FOXE1 Gene Play A Role?
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2022)

AIP gene germline variants in adult Polish patients with apparently sporadic pituitary macroadenomas
por: Trofimiuk-Müldner, Małgorzata, et al.
Publicado: (2023)

Imaging of inflamed carotid artery atherosclerotic plaques with the use of (99m)Tc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients
por: Opalinska, Marta, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

MON-300 AIP Gene Germline Mutations in Non-Selected Patients with Apparently Sporadic Pituitary Macrodenomas
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2020)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lf9ej8sr6d0bvis84f6f67pjhd